Thrombolytic toxicity: Blood brain barrier disruption in human ischemic stroke

Cerebrovascular Diseases

Volumn 25, Issue 4, 2008, Pages 338-343

  Kidwell, Chelsea S ^a,b,d   Latour, Larry ^c   Saver, Jeffrey L ^d   Alger, Jeffry R ^d   Starkman, Sidney ^d   Duckwiler, Gary ^d   Jahan, Reza ^d   Vinuela, Fernando ^d   Kang, Dong Wha ^e   Warach, Steven ^c  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^d UCLA MEDICAL CENTER   (United States)

^e Asan Medical Center   (South Korea)

Author keywords

Blood brain barrier; Ischemic stroke; Mechanical embolectomy; MRI; Thrombolysis

Indexed keywords

GADODIAMIDE; GADOLINIUM PENTETATE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ADULT; AGE; AGED; ARTICLE; BLOOD BRAIN BARRIER; BLOOD BRAIN BARRIER DISRUPTION; CEREBROSPINAL FLUID; CEREBROVASCULAR ACCIDENT; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MECHANICAL THROMBECTOMY; NEUROTOXICITY; NEUROVASCULAR TOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTOR VARIABLE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD-BRAIN BARRIER; BRAIN ISCHEMIA; EMBOLECTOMY; FEMALE; FIBRINOLYTIC AGENTS; GADOLINIUM; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 42349095894     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000118379     Document Type: Article

References (21)

1. NINDS rt-PA Stroke Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
2. Furlan A, Higashida R, Wechsler L, et al: Intra-arterial prourokinase for acute ischemic stroke - The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999;282:2003-2011.
3. Smith WS, Sung G, Starkman S, et al: Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI Trial. Stroke 2005;36:1432-1438.
4. Latour LL, Kang DW, Ezzeddine MA, et al: Early blood-brain barrier disruption in human focal brain ischemia. Ann Neurol 2004;56:468-477.
5. Dechambre SD, Duprez T, Grandin CB, et al: High signal in cerebrospinal fluid mimicking subarachnoid haemorrhage on FLAIR following acute stroke and intravenous contrast medium. Neuroradiology 2000;42:608-611.
6. TIMI Study Group: The Thrombolysis in Myocardial Infarction (TIMI) trial: phase I findings. New Engl J Med 1985;312:932-936.
7. Kidwell CS, Saver JL, Carneado J, et al: Predictors of hemorrhagic transformation in patients receiving intra-arterial thrombolysis. Stroke 2002;33:717-724.
8. Adams HP Jr, Adams RJ, Brott T, et al: Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke 2003;34:1056-1083.
9. Wang X, Tsuji K, Lee SR, et al: Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 2004;35:2726-2730.
10. Del Zoppo GJ: tPA: a neuron buster, too? Nat Med 1998;4:148-150.
11. Kaur J, Zhao Z, Klein GM, et al: The neurotoxicity of tissue plasminogen activator? J Cereb Blood Flow Metab 2004;24:945-963.
12. Tsirka SE, Gualandris A, Amaral DG, Strickland S: Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 1995;377:340-344.
13. Tsirka SE, Rogove AD, Strickland S: Neuronal cell death and tPA. Nature 1996;384:123-124.
14. Wang YF, Tsirka SE, Strickland S, et al: Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 1998;4:228-231.
15. Nicole O, Docagne F, Ali C, et al: The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001;7:59-64.
16. Liu D, Cheng T, Guo H, et al: Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat Med 2004;10:1379-1383.
17. Sumii T, Lo EH: Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 2002;33:831-836.
18. Wang X, Lee SR, Arai K, et al: Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 2003;9:1313-1317.
19. Yepes M, Sandkvist M, Moore EG, et al: Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 2003;112:1533-1540.
20. Pfefferkorn T, Rosenberg GA: Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke 2003;34:2025-2030.
21. Jiang Q, Ewing JR, Ding GL, et al: Quantitative evaluation of BBB permeability after embolic stroke in rat using MRI. J Cereb Blood Flow Metab 2005;25:583-592.